CINV Market Forecast (2026–2030): Expansion Trends
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Expected To Change From 2026 To 2030?
The market size for chemotherapy-induced nausea and vomiting (cinv) has experienced strong growth in recent years. It is projected to expand from $3.13 billion in 2025 to $3.35 billion in 2026, at a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be attributed to the increasing use of highly emetogenic chemotherapy, a rising awareness of treatment side effects, the availability of advanced antiemetic drugs, the expansion of oncology treatment programs, and improved clinical guidelines for cinv management.
The chemotherapy-induced nausea and vomiting (CINV) market is projected to witness substantial growth over the next few years. It is forecast to grow to $4.57 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.0%. This anticipated expansion during the forecast period is driven by increasing demand for next-generation antiemetics, the rising adoption of personalized antiemetic therapy, the expansion of outpatient chemotherapy services, a growing emphasis on adherence to treatment protocols, and advancements in sustained-release formulations. Significant trends expected in the forecast period include a greater adoption of combination antiemetic regimens, an increased use of long-acting CINV drugs, a strengthening focus on patient-centric treatment approaches, the broadening of preventive CINV management protocols, and an enhanced emphasis on quality-of-life outcomes.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Affecting The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Demand?
The rising occurrence of cancer is projected to stimulate the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the future. Cancer refers to a condition where certain body cells grow uncontrollably and disseminate to other parts of the body. With the continuous increase in cancer incidents, there is a stronger motivation to create more potent and specific anti-emetic solutions to mitigate CINV, a difficult side effect of chemotherapy. This increased emphasis on managing CINV has resulted in progress in understanding its fundamental processes and creating new treatments. For example, in January 2023, the American Cancer Society (ACS), a US-based volunteer health organization dedicated to eradicating cancer, projected that in the United States, there would be 1.9 million new cancer cases (around 5,370 cases daily) and 609,820 cancer deaths (approximately 1,670 deaths daily) in 2023. Consequently, the growing incidence of cancer will fuel the chemotherapy-induced nausea and vomiting (CINV) market.
Which Segment Types Are Examined In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segment Study?
The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –
1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
What Trends Are Influencing Changes In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Major companies in the chemotherapy-induced nausea and vomiting (CINV) market are focusing on new product innovations, such as fixed intravenous antiemetics, to achieve a competitive advantage. A fixed intravenous antiemetic is a specific quantity of medication given through an IV to prevent or treat nausea and vomiting, often used in chemotherapy or after surgery. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based producer of pharmaceuticals, generics, and over-the-counter (OTC) items, released AKYNZEO I.V. in India. This was the first fixed intravenous antiemetic combination developed to prevent chemotherapy-induced nausea and vomiting (CINV). The product combines netupitant and palonosetron, targeting both the early and later phases of nausea and vomiting. It offers convenience with a single dose, leads to improved complete response rates, and enhances the quality of life for cancer patients. Clinical studies demonstrate its particular usefulness for patients undergoing highly emetogenic chemotherapy.
Which Players Are Part Of The Competitive Landscape Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Get The Full Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report:
Where Is The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Primarily Concentrated By Region?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026, By The Business Research Company
Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026
Chemotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Chemotherapy Induced Anemia Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
